TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Consultancies and service providers at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
9 consultancies and service providers are at TIDES Europe 2026 — 14 presentations on the program. Most represented: Livinovea (1 on the program), Coswald Consulting (1 on the program), ML Consult (1 on the program). 4 of them have their own page in this guide. As of Nov 2, 2026.
Focus
Top represented
Showing 1–9 of 9 organizations
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Swiss consultancy providing business, operational and technical support, including tech transfer and process optimization, to pharma, biotech and CDMOs. | Talk Tue Nov 3 09:45–10:25 Chair Tue Nov 3 09:00–09:05 Workshop Moderators’ Introduction Which early manufacturing and quality decisions set what an oligonucleotide drug costs to produce, and when in development they should be taken. Chair Thu Nov 5 08:00–08:05 |
Consultancy helping drug manufacturers improve quality and production systems, including chemistry, manufacturing and controls for oligonucleotides. | Talk Tue Nov 3 11:25–12:00 Keynote Tue Nov 3 09:00–09:10 Moderator’s Welcome and Opening Remarks Why manufacturing and quality planning for oligonucleotide drugs should start early and span test methods, chemistry choices and raw-material supply. |
Consultancy working on oligonucleotide chemistry, manufacturing and controls from the early discovery stage onward. | Talk Tue Nov 3 09:10–09:45 Drug Substance and Drug Product and How CMC Early in the Discovery Lifecycle Can Help Why a careful handover from making the drug substance to making the finished product makes the paperwork for first clinical trials easier. Chair Thu Nov 5 13:55–14:00 |
Consultancy advising on oligonucleotide manufacturing and sourcing nucleic acid raw materials for drug and diagnostics developers. | Chair Tue Nov 3 13:10–13:15 Chairperson’s Remarks OligonucleotidesPeptides Chair Wed Nov 4 13:55–14:00 |
Drees & Sommer Stuttgart, Germany | |
Engineering, consulting and project management firm that plans and builds facilities, including life science manufacturing sites. | Talk Wed Nov 4 11:15–11:45 Enzymatic Ligation and Manufacturing Microbial Control Consdierations How joining oligonucleotide pieces with enzymes in water-based steps raises new risks of microbial growth, and what that means for regulated manufacturing. |
Informa Connect London, United Kingdom | |
Event organizer that runs TIDES Europe, its Obesity Science & Innovation Europe symposium and other life science conferences. | Talk Fri Nov 6 08:30–08:40 |
Life sciences consultancy advising biotech and pharmaceutical companies on CMC and regulatory strategy. | Talk Tue Nov 3 09:45–10:20 Future-Proofing Oligonucleotide Manufacturing: Starting-Material Strategy for Scale-Up, Platform Change, and Commercial Supply Continuity Why the choice and control of starting materials decides whether oligonucleotide manufacturing survives scale-up, a platform switch or a site transfer. |
MW Mike Webb Pharma | |
Consultancy advising on oligonucleotide CMC development, analysis and manufacture from preclinical work to marketing submission. | Chair Thu Nov 5 13:55–14:00 |
SB Sinawali Biotechnology Solutions | |
Consultancy working on bioanalytical and analytical methods for oligonucleotide, mRNA and antibody-conjugated oligonucleotide drugs. | Talk Tue Nov 3 10:50–11:25 Bioanalytical and Analytical Approaches and Alignment A review of the now-standard laboratory tests for oligonucleotide drugs, and what changes for mRNA and for oligonucleotides attached to antibodies. |
Find buyers from consultancies and service providers
Tell us what you sell and we’ll find the people at these consultancies and service providers most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse TIDES Europe 2026 by
Organization type
Focus
Exhibit hall
Everyone
Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction